Dan Bradbury, Board Chair
Mr. Bradbury is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm.
Mr. Bradbury is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Mr. Bradbury worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He also serves on the board of directors of Corcept Therapeutics (CORT), Geron Corporation (GERN), Illumina, Inc. (ILMN) and Castle Biosciences, Inc., the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee.
Mr. Bradbury currently serves on the University of California San Diego’s Rady School of Management's Advisory Council, the RAND Health Board of Advisors and the University of Miami's Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Joe C. Cook, Jr, Board Member
Mr. Cook is a principal and co-founder of Mountain Group Capital. Mr. Cook is a founder and Past-Chairman of the Board of Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) a biotechnology company in Cambridge, MA where he continues to serve as a director. Also, Mr. Cook serves as a director of Corcept Therapeutics, Inc. (NASDAQ: CORT) a biopharmaceutical company in Palo Alto, CA. Mr. Cook served as Chairman of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) from 1998 to 2009 and was Chief Executive Officer from 1998 to 2003. In 2009, Mr. Cook received the Pinnacle Award for Life Science Leadership from the Rady School of Management at the University of California at San Diego.
Mr. Cook retired as a Group Vice-President, Global Operations, of Eli Lilly and Company in 1993 after more than 28 years of service. During his career at Lilly he served in various senior executive positions including: manufacturing, engineering, finance, sales and marketing and general management. Mr. Cook took a leave of absence from Eli Lilly and Co. in 1976 and was employed by the US International Trade Commission in Washington, DC as a part of the President’s Executive Exchange Program.
Mr. Cook serves as Chairman of the Board of Mercy Ministries International, Inc. with headquarters in Nashville, TN. He is also a past Chair and current member of the University of Tennessee College of Engineering Advisory Board. In 1999, Mr. Cook received the Nathan W. Dougherty Award from the University of Tennessee for distinguished service in the engineering profession. Mr. Cook also serves on the national board of the American Diabetes Association and is Chairman of the board of Life Science Tennessee. Mr. Cook also serves as Chairman of Diabetes Care Group and on the boards of Castle Biosciences and Clinical Products. He was a co-founder and serves on the boards of Device Innovation Group and Diagnovus.
Mr. Cook graduated from the University of Tennessee in 1965 where he received a BS in Engineering with High Honors and was a UT Torchbearer.
Garheng Kong, MD, PhD, Board Member
Dr. Kong is the Founder and Managing Partner of HealthQuest Capital, a healthcare focused investment firm, and has been a healthcare investor since 2000. He was a General Partner at Sofinnova Ventures and Intersouth Partners. Dr. Kong has served as chairman and director on the boards of numerous companies, and operated as interim CEO for two venture-backed companies. Specifically, he served as the founding investor and Chairman of Cellective Therapeutics (acquired by AstraZeneca), Chairman of Serenex (acquired by Pfizer), Chairman of Novamin Technologies (acquired by GlaxoSmithKline), Chairman of Cempra Pharmaceuticals (Nasdaq: CEMP), and lead investor of the first financing for Alimera Sciences (Nasdaq: ALIM). Dr. Kong has also led investments in Viamet Pharmaceuticals (Chairman), Proteon Therapeutics, Applied Genetic Technology Corporation (Nasdaq: AGTC), TransEnterix (NYSE: TRXC), Calibra Medical (acquired by J&J), Athenix (acquired by Bayer, board observer), Aldagen (acquired by Cytomedix), Histogenics (Chairman), Salveo Specialty Pharmacy, SARcode Bioscience Inc. (acquired by Shire) and First Aid Beverages, Inc. Additionally he sits on the board of Laboratory Corporation of America (NYSE: LH) and the Duke University Medical Center Board of Visitors.
Dr. Kong serves or has served on the boards of directors of the SEBIO organization, the North Carolina Biotechnology Center, the Council for Entrepreneurial Development (CED), the Hamner Institutes for
Life Sciences, the North Carolina Medical Device Organization, the University of Florida Biotechnology Council, the University of Virginia Ivy Foundation, the Pennsylvania Life Sciences Greenhouse, the Southeast Universities Research Association, the Investor Advisory Board for the Florida Institute for the Commercialization of Public Research, Corporate Chaplains of America and the Duke Medical Center Institutional Review Board (IRB).
Prior to his investing career, Dr. Kong spent time at GlaxoSmithKline, McKinsey & Company, and TherOx. He received his M.D. (Medical Scientist Training Program), Ph.D. in Biomedical Engineering, and M.B.A. from Duke University, where he also served on the faculty. He also holds B.S. degrees in Chemical Engineering and Biological Sciences from Stanford University.
Derek Maetzold, President, CEO, and Board Member
Mr. Maetzold is the founder, President, CEO, and Board member of Castle Biosciences, Inc.
He has been a leader in biopharmaceuticals for over 25 years, working in leadership roles in both biotechnology and traditional pharmaceutical companies. Prior to founding Castle Biosciences, Mr. Maetzold was an Officer and Vice President, Marketing and Sales at Encysive Pharmaceuticals, a publicly traded company that was acquired by Pfizer. Prior to Encysive, Mr. Maetzold worked in business development and new product development at Schering Corporation (now Merck). Previous experience included positions at Integrated Communications, Amylin Pharmaceuticals (now BMS) and Sandoz (now Novartis). Derek started in field sales at Sandoz, eventually working into leadership positions in both U.S. and international marketing.
Mr. Maetzold attended George Mason University, where he received a BS in Biology before completing additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside.